Jove
Visualize
Contáctanos

Videos de Conceptos Relacionados

Preclinical Development: Overview01:28

Preclinical Development: Overview

5.7K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.7K
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K
Drug Discovery: Overview01:26

Drug Discovery: Overview

10.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.9K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

1.1K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.1K
In Vitro Drug Release Testing: Overview, Development and Validation01:10

In Vitro Drug Release Testing: Overview, Development and Validation

269
In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
269
Drug Regulation01:25

Drug Regulation

2.7K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
2.7K

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Basic Science and Pathogenesis.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Characterization and risk prioritization of PFAS via nontarget screening in soil and maize near a fluoropolymer manufacturing facility.

Journal of hazardous materials·2025
Same author

PBM alleviates depression and anxiety like behaviors in mice: insight from local field potential.

Behavioral and brain functions : BBF·2025
Same author

The early alteration of brainstem and cerebellum, and their relationship with cerebral cortex: an <i>in vivo</i> fetal magnetic resonance imaging assessment.

Quantitative imaging in medicine and surgery·2025
Same author

Metal-Phase Protection Suppresses Bi Leaching for Durable Acidic CO<sub>2</sub> Electroreduction to Formic Acid.

Angewandte Chemie (International ed. in English)·2025
Same author

Sex-specific alterations in brain network topology in methamphetamine use disorder: A graph theory-based fMRI study.

Drug and alcohol dependence·2025
Same journal

Multimorbidity burden and patterns associated with DeepBrainNet-derived brain-age gap in dementia-free older adults: A community-based study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Reply to "Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities".

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Correlates and predictors of self-efficacy among dementia caregivers: D-CARE findings.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

What should convince a clinician of disease modification in Alzheimer's disease clinical trials?

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Primary cilia-extracellular vesicle crosstalk in Alzheimer's disease: Emerging mechanisms and biomarker potential.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Ver todos los artículos relacionados
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Video Experimental Relacionado

Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K

Desarrollo de Fármacos

Dinghao An1, Xiaotong Li2, Yun Xu3

  • 1Peking Union Medical College, Beijing, Beijing, China.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 25, 2025
PubMed
Resumen
Este resumen es generado por máquina.

La combinación de bloqueadores de los canales de calcio Cav2.1 con anticuerpos monoclonales dirigidos contra amiloide puede reducir las reacciones adversas como la ARIA-E en pacientes con enfermedad de Alzheimer. Este enfoque tiene como objetivo mejorar la seguridad del tratamiento y los resultados de los pacientes.

Palabras clave:
enfermedad de Alzheimeranticuerpos monoclonalesbloqueadores de los canales de calcioARIA-Edesarrollo de fármacosneurocienciafarmacologíainmunología

Más Videos Relacionados

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

446

Videos de Experimentos Relacionados

Last Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K
In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

446

Área de la Ciencia:

  • Neurociencia
  • Farmacología
  • Inmunología

Sus antecedentes:

  • Los tratamientos para la enfermedad de Alzheimer que utilizan anticuerpos monoclonales dirigidos contra amiloide están aprobados por la FDA.
  • Las reacciones adversas, incluidas ARIA-E (edema) y ARIA-H (hemorragia), pueden afectar negativamente el pronóstico del paciente.
  • Comprender y mitigar estos efectos secundarios es crucial para una terapia eficaz del Alzheimer.

Objetivo del estudio:

  • Evaluar el potencial terapéutico de la combinación de bloqueadores de los canales de calcio Cav2.1 con anticuerpos monoclonales anti-beta-amiloide para la enfermedad de Alzheimer.
  • Investigar el mecanismo por el cual esta combinación puede reducir la aparición de ARIA-E.
  • Explorar mejoras en la función cognitiva y la seguridad general del tratamiento.

Principales métodos:

  • Generación de hipótesis basada en evidencia existente.
  • Validación preliminar del enfoque terapéutico combinado.
  • Los planes futuros incluyen estudios en células y animales para la validación de eficacia y seguridad.

Principales resultados:

  • Los bloqueadores de Cav2.1 (p. ej., Nimodipina) dilatan los vasos cerebrales, protegen la barrera hematoencefálica y mantienen la circulación cerebral.
  • Promueven la vasodilatación, ayudando a la eliminación de beta-amiloide y previniendo la acumulación de factores inflamatorios.
  • Este mecanismo facilita la eliminación de factores inflamatorios y especies reactivas de oxígeno, rescatando potencialmente las neuronas.

Conclusiones:

  • La combinación de bloqueadores de los canales de calcio Cav2.1 con anticuerpos monoclonales presenta una estrategia novedosa para el tratamiento del Alzheimer.
  • Esta intervención puede reducir la incidencia y gravedad de ARIA-E.
  • Se necesita más investigación para confirmar la eficacia y seguridad en entornos clínicos.